Relationship Between Steroid Hormone Profile and Premenstrual Syndrome in Women Consulting for Infertility or Recurrent Miscarriage

Overview

Journal Reprod Sci

Publisher Springer

Specialty Reproductive Medicine

Date 2023 Oct 18

PMID 37853154

Authors

Joseph V Turner

Lucas A McLindon

Damien V Turner

Yolaine Alefsen

Rene Ecochard

Affiliations

Soon will be listed here.

Abstract

To determine the relationships between luteal-phase steroidal hormonal profile and PMS for a large number of women attending a dedicated fertility clinic. This was a retrospective cross-sectional study on women attending a hospital-based clinic for fertility concerns and/or recurrent miscarriage. All participants were assessed with a women's health questionnaire which also included evaluation of premenstrual symptoms. Day of ovulation was identified based on the peak mucus symptom assessed by the woman after instruction in a fertility awareness-based method (FABM). This enabled reliable timing of luteal-phase serum hormone levels to be taken and analysed. Between 2011 and 2021, 894 of the 2666 women undertaking the women's health assessment had at least one evaluable serum luteal hormone test. Serum progesterone levels were up to 10 nmol/L lower for symptomatic women compared with asymptomatic women. This difference was statistically significant (p < 0.05) for the majority of PMS symptoms at ≥ 9 days after the peak mucus symptom. A similar trend was observed for oestradiol but differences were generally not statistically significant. ROC curves demonstrated that steroid levels during the luteal phase were not discriminating in identifying the presence of PMS symptoms. Blood levels for progesterone were lower throughout the luteal phase in women with PMS, with the greatest effect seen late in the luteal phase.

References

Redei E, Freeman E . Preliminary evidence for plasma adrenocorticotropin levels as biological correlates of premenstrual symptoms. Acta Endocrinol (Copenh). 1993; 128(6):536-42. DOI: 10.1530/acta.0.1280536. View

Hammarback S, Damber J, Backstrom T . Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J Clin Endocrinol Metab. 1989; 68(1):125-30. DOI: 10.1210/jcem-68-1-125. View

Reid R, Soares C . Premenstrual Dysphoric Disorder: Contemporary Diagnosis and Management. J Obstet Gynaecol Can. 2017; 40(2):215-223. DOI: 10.1016/j.jogc.2017.05.018. View

Rubinow D, Hoban M, Grover G, Galloway D, Roy-Byrne P, Andersen R . Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol. 1988; 158(1):5-11. DOI: 10.1016/0002-9378(88)90765-x. View

Lovick T, Guapo V, Anselmo-Franci J, Loureiro C, Faleiros M, Del Ben C . A specific profile of luteal phase progesterone is associated with the development of premenstrual symptoms. Psychoneuroendocrinology. 2016; 75:83-90. DOI: 10.1016/j.psyneuen.2016.10.024. View

Di Florio A, Alexander D, Schmidt P, Rubinow D . Progesterone and plasma metabolites in women with and in those without premenstrual dysphoric disorder. Depress Anxiety. 2018; 35(12):1168-1177. PMC: 7440927. DOI: 10.1002/da.22827. View

Backstrom T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G . Allopregnanolone and mood disorders. Prog Neurobiol. 2013; 113:88-94. DOI: 10.1016/j.pneurobio.2013.07.005. View

Hilgers T, Daly K, Prebil A, Hilgers S . Cumulative pregnancy rates in patients with apparently normal fertility and fertility-focused intercourse. J Reprod Med. 1992; 37(10):864-6. View

Hsiao C, Liu C, Hsiao M . No correlation of depression and anxiety to plasma estrogen and progesterone levels in patients with premenstrual dysphoric disorder. Psychiatry Clin Neurosci. 2004; 58(6):593-9. DOI: 10.1111/j.1440-1819.2004.01308.x. View

10.

Vigil P, Lyon C, Flores B, Rioseco H, Serrano F . Ovulation, a sign of health. Linacre Q. 2017; 84(4):343-355. PMC: 5730019. DOI: 10.1080/00243639.2017.1394053. View

11.

Abdullah S, Bouchard T, Leiva R, Boehringer H, Iwaz J, Ecochard R . Distinct urinary progesterone metabolite profiles during the luteal phase. Horm Mol Biol Clin Investig. 2022; 44(2):137-144. DOI: 10.1515/hmbci-2022-0065. View

12.

Cunningham J, Yonkers K, OBrien S, Eriksson E . Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry. 2009; 17(2):120-37. PMC: 3098121. DOI: 10.1080/10673220902891836. View

13.

Vanselow W, Dennerstein L, Greenwood K, de Lignieres B . Effect of progesterone and its 5 alpha and 5 beta metabolites on symptoms of premenstrual syndrome according to route of administration. J Psychosom Obstet Gynaecol. 1996; 17(1):29-38. DOI: 10.3109/01674829609025661. View

14.

Girdler S, Straneva P, Light K, Pedersen C, Morrow A . Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry. 2001; 49(9):788-97. DOI: 10.1016/s0006-3223(00)01044-1. View

15.

Magill P . Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. progesterone Study Group. Br J Gen Pract. 1995; 45(400):589-93. PMC: 1239433. View

16.

Frank-Herrmann P, Heil J, Gnoth C, Toledo E, Baur S, Pyper C . The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple's sexual behaviour during the fertile time: a prospective longitudinal study. Hum Reprod. 2007; 22(5):1310-9. DOI: 10.1093/humrep/dem003. View

17.

Timby E, Backstrom T, Nyberg S, Stenlund H, Wihlback A, Bixo M . Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study. Psychopharmacology (Berl). 2016; 233(11):2109-2117. DOI: 10.1007/s00213-016-4258-1. View

18.

Backstrom T, Bixo M, Stromberg J . GABAA Receptor-Modulating Steroids in Relation to Women's Behavioral Health. Curr Psychiatry Rep. 2015; 17(11):92. DOI: 10.1007/s11920-015-0627-4. View

19.

Billings E, Brown J, BILLINGS J, Burger H . Symptoms and hormonal changes accompanying ovulation. Lancet. 1972; 1(7745):282-4. DOI: 10.1016/s0140-6736(72)90291-7. View

20.

Hilgers T, ABRAHAM G, Cavanagh D . Natural family planning. I. The peak symptom and estimated time of ovulation. Obstet Gynecol. 1978; 52(5):575-82. View